# Oral GLP-1 Diabetes Treatments Ascletis Reports Positive Phase II Results for ASC30 By Mursal Rahman | Written with AI assistance | Published 2026-10-30 | Lifestyle Source: Trend Hunter, https://www.trendhunter.com/trends/oral-glp-1-diabetes-treatments References: [prnewswire](https://www.prnewswire.com/news-releases/ascletis-oral-small-molecule-glp-1--asc30--demonstrated-placebo-adjusted-hba1c-reduction-of-1-7-at-12-weeks-from-its-us-phase-ii-study-in-participants-with-diabetes-302922287.html)  Ascletis Pharma is advancing [oral GLP-1 diabetes treatments](https://www.trendhunter.com/trends/glp1-medication) with positive Phase II results for ASC30, an investigational tablet designed to manage blood sugar and support weight reduction. Unlike injectable therapies, the medication is taken once daily, offering a potential alternative for people with type 2 diabetes. The 13-week U.S. study involved 100 participants and demonstrated placebo-adjusted HbA1c reductions of 1.6% to 1.7% across three dosage groups. Participants also experienced [weight reductions](https://www.trendhunter.com/trends/novo-nordisk-1) ranging from 3.8% to 4.4% compared with placebo. No participants discontinued because of gastrointestinal side effects, and researchers reported no drug-related serious adverse events or liver safety concerns. For Ascletis, these findings support further clinical development and expand ASC30's potential beyond [obesity treatment](https://www.trendhunter.com/trends/suite-of-wellness-solutions). If future trials confirm its effectiveness and safety, the medication could strengthen the company's pharmaceutical portfolio and provide patients with another oral treatment option. Image Credit: Ascletis ## Trend Insights (Trend Hunter) - Score: 6.1/10 - Popularity: 33% | Activity: 50% | Freshness: 100% - Audience gender: 50% men, 50% women - Primary generations: Millennial, Gen X - Top markets: North America ## Categories [Trend Hunter](https://www.trendhunter.com/trends) > [Lifestyle](https://www.trendhunter.com/lifestyle) > [Health](https://www.trendhunter.com/health) ## Key Themes ### Key Themes Behind This Trend - **Oral Metabolic Therapies:** Tablet-based GLP-1 treatments could reshape diabetes and obesity care by reducing dependence on injections while improving daily treatment convenience. - **Dual Diabetes-weight Management:** Combined blood sugar control and weight reduction signals a growing shift toward metabolic treatments that address overlapping chronic health needs. - **Patient-friendly Chronic Care:** Improved tolerability and once-daily dosing create space for therapies that fit more easily into long-term patient routines. ### Where This Applies - **Pharmaceuticals:** Clinical-stage drug developers may find new portfolio value in oral incretin therapies that compete with leading injectable metabolic medications. - **Diabetes Care:** Care providers and treatment platforms could benefit from expanded medication formats that support adherence among people managing type 2 diabetes. - **Obesity Treatment:** The emergence of oral GLP-1 candidates adds competitive pressure to weight management markets currently shaped by injectable therapies. ## Related on Trend Hunter - [GLP-1 Biomimetic Supplements](https://www.trendhunter.com/trends/wlp-1.md) - [Food-Grade GLP-1 Stimulators](https://www.trendhunter.com/trends/glp-1-formula.md) - [Needle-Free Peptide Therapies](https://www.trendhunter.com/trends/needle-free-peptide-therapies.md) - [Long-Acting Metabolic Implants](https://www.trendhunter.com/trends/Long-acting-metabolic-implants.md) - [Same-Day GLP-1 Services](https://www.trendhunter.com/trends/amazon-pharmacy-glp-1.md) - [Oral GLP-1 Medicines](https://www.trendhunter.com/trends/wegovy-pill.md) - [Medical-Grade Weight Management](https://www.trendhunter.com/trends/Medical-grade-weight-management.md) - [GLP-1 Medication-Offering Health Platforms](https://www.trendhunter.com/trends/futurhealth.md) - [Once-Weekly Basal Insulins](https://www.trendhunter.com/trends/daily-insulin-burden.md)